Publications by authors named "M E Taplin"
Background: Lu-prostate-specific membrane antigen (PSMA)-617 (LuPSMA) is a radionuclide therapy approved for patients with PSMA-avid metastatic castrate-resistant prostate cancer (mCRPC). We evaluated whether alterations in the DNA damage repair (DDR) pathway were associated with outcomes to LuPSMA.
Patients And Methods: We identified an institutional cohort of men (n = 134) treated with ≥2 cycles of LuPSMA who had panel-based germline and/or tumor genomic sequencing.
Article Synopsis
- Advances in molecular diagnostics are transforming how prostate, renal, and urothelial cancers are assessed, offering more accurate detection methods for disease burden and minimal residual disease (MRD).
- A literature review from 1980-2024 highlights emerging radiographic and molecular tools aimed at improving disease quantification and monitoring through innovative technologies and biomarker-informed trials.
- New developments, like novel radiotracers and molecular detection methods (e.g., circulating tumor DNA), provide insights into disease mechanisms and have the potential to enhance clinical management, although full MRD application is still in progress.
Current US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high-level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions that are unanswered by prospective trials but nonetheless encountered in day-to-day practice. To address these practical questions, the 2024 US Prostate Cancer Conference (USPCC 2024) was created to generate US-focused expert clinical decision-making guidance for circumstances in which level 1 evidence is lacking. At the second annual USPCC meeting (USPCC 2024), a multidisciplinary panel of experts convened to discuss ongoing clinical challenges related to 5 topic areas: biochemical recurrence; metastatic, castration-sensitive prostate cancer; poly [ADP-ribose] polymerase inhibitors; prostate-specific membrane antigen radioligand therapy; and metastatic, castration-resistant prostate cancer.
View Article and Find Full Text PDFArticle Synopsis
- The study examines whether "total therapy," which includes various treatments for oligometastatic hormone-sensitive prostate cancer (omHSPC), can result in long-term remission.
- A total of 89 patients were studied, with findings indicating that 45% remained progression-free at three years, suggesting potential long-term remission and possible cure in some cases.
- The research highlights the need for further prospective trials to confirm these outcomes and better understand the effectiveness of total therapy for omHSPC.
Article Synopsis
- The study investigates how AI-generated measurements of intraprostatic tumor volume from MRI scans can predict the risk of metastasis in prostate cancer patients treated with either radiation therapy or radical prostatectomy.
- A total of 732 patients were involved, with findings indicating that a larger tumor volume significantly correlated with increased rates of metastasis during the follow-up periods, which averaged 6.9 years for radiation therapy and 5.5 years for surgery.
- The research highlighted that the AI-based volume measurements provided independent prognostic information, outperforming traditional risk categorization methods in predicting long-term metastasis.